

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FIL	ING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/798,096	03	3/11/2004	Rea-Min Chu	P/741-176 6503	
2352	7590	06/17/2005	EXAMINER		
		R GERB & SOFF	LIETO, LOUIS D		
1180 AVENUE OF THE AMERICAS NEW YORK, NY 100368403				ART UNIT	PAPER NUMBER
	•			1632	

DATE MAILED: 06/17/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-90C (Rev. 10/03)

	Application No.	Applicant(s)					
Office Action Summers	10/798,096	CHU ET AL.					
Office Action Summary	Examiner	Art Unit					
	Louis D. Lieto	1632					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1) Responsive to communication(s) filed on	_•						
2a) ☐ This action is <b>FINAL</b> . 2b) ☒ This	This action is FINAL. 2b)⊠ This action is non-final.						
3) Since this application is in condition for allowan	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under E	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4) ⊠ Claim(s) 1-16 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration.  5) □ Claim(s) is/are allowed.  6) □ Claim(s) is/are rejected.  7) □ Claim(s) is/are objected to.  8) ⊠ Claim(s) 1-16 are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:						

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-14 and 16, drawn to a complex immuno-gene medical composition for inhibiting tumor cells, comprising DNA Sequences SEQ ID NO 1 and SEQ ID NO 2, and a method of using the composition to inhibit the growth of tumor cells, classified in class 514, subclass 44.
- II. Claim 15, drawn to a complex immuno-gene medical composition for inhibiting tumor cells, comprising a therapeutic amount of IL-6 and IL-15, classified in class 530, subclass 350.

The inventions are distinct, each from the other because of the following reasons:

Inventions I, and II are patentably distinct inventions for the following reasons. In the instant case the different invention of group I is drawn to a complex immuno-gene medical composition for inhibiting tumor cells, comprising DNA Sequences SEQ ID NO 1 and SEQ ID NO 2, and a method of using the composition to inhibit the growth of tumor cells, while the invention of group II is drawn to drawn to a complex immuno-gene medical composition for inhibiting tumor cells, comprising a therapeutic amount of IL-6 and IL-15. The invention of group I is drawn to a composition comprising two DNA sequences, which is quite different from the invention of group II. The invention of group II is drawn to a composition comprising IL-6 and IL-15. The

invention of group II can be made entirely with the proteins of IL-6 and IL-15 and does not require the DNA sequences of Group I. Neither invention requires the other.

Page 3

Furthermore, searching the inventions of groups I and II together would impose a serious search burden. In the instant case, the search of the DNA sequences and the cytokines IL-6 and IL-15 are not coextensive. The inventions of groups I and II have a separate status in the art as shown by their different classifications. As such, it would be burdensome to search the inventions of groups I and II together.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

This application contains claims directed to the following patentably distinct species of the claimed invention: Group I is drawn to the following patentably distinct species of tumor cells:

- a) primary breast carcinoma
- b) advanced renal cell carcinoma
- c) melanoma
- d) prostate cancer
- e) lung carcinoma
- f) colon tumors
- g) bladder tumors
- h) skin tumors

Application/Control Number: 10/798,096 Page 4

Art Unit: 1632

i) endometrium tumors

j) poultry T lymphoma

k) CTVT

l) Thyreoglandular cancer

m) Hepatocellular cancer

n) Meth A tumor

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-16 are generic.

This application contains claims directed to the following patentably distinct species of the claimed invention: Group I is drawn the following patentably distinct species of administering plasmids:

- a) plasmid transformation
- b) particle gun
- c) muscle electroporation

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-14 and 16 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Lou Lieto whose telephone number is (571) 272-2932. The examiner can normally be reached on Monday-Friday, 9am-5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Ram Shukla can be reached on (571) 272-0735. The fax phone number for the organization where this application or proceeding is assigned is (571)-272-0735. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Patent applicants with problems or questions regarding electronic images that can be viewed in the PAIR can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6

Page 6

am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Dr. Louis D. Lieto Patent Examiner Art Unit 1632

RAM R. SHUKLA, PH.U.